Literature DB >> 26626500

Review of Cutaneous Graft-vs-Host Disease.

R Ballester-Sánchez1, M Navarro-Mira2, J Sanz-Caballer3, R Botella-Estrada2.   

Abstract

Graft-vs-host disease (GVHD) is a multisystem disease that arises as a complication of allogeneic hematopoietic stem cell transplant. It is due to recognition of the recipient's tissues by immune cells from the donor. The skin and mucous membranes are the organs most commonly affected. GVHD is classified as acute or chronic depending on the pathophysiology and clinical presentation. Acute GVHD typically presents with the triad of rash, diarrhea, and hyperbilirubinemia, and treatment is based on systemic corticosteroid and immunosuppressant therapy. The cutaneous manifestations of chronic GVHD are divided into sclerodermiform and nonsclerodermiform, and the mucous membranes and skin appendages may also be affected. The diagnosis is mainly clinical, but skin biopsy can help in doubtful cases. Treatment can be topical, systemic, or physical, depending on the size, site, and depth of the lesions and the involvement of other organs.
Copyright © 2015 AEDV. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Cutaneous graft-versus-host disease; Dermatopatología; Dermopathology; Enfermedad injerto contra huésped cutánea; Hematopoietic stem cell transplant; Trasplante de progenitores hematopoyéticos

Mesh:

Year:  2015        PMID: 26626500     DOI: 10.1016/j.ad.2015.10.003

Source DB:  PubMed          Journal:  Actas Dermosifiliogr        ISSN: 0001-7310


  2 in total

1.  Graft-versus-host disease: A rare complication of device implantation.

Authors:  Jack Xu; Thomas E Watts; Gareth Tobler; Hakan Paydak
Journal:  HeartRhythm Case Rep       Date:  2016-07-27

2.  Gene expression profile of chronic oral graft-versus-host disease.

Authors:  Giselle Rocha Pinto; Viviane Almeida Sarmento; Paulo Cirino de Carvalho-Filho; Vitor Antonio Fortuna; Ryan Dos Santos Costa; Rogério Reis Conceição; Soraya Castro Trindade
Journal:  PLoS One       Date:  2022-04-29       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.